If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach

January 11, 2022

2 Views

If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach

Q. If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach :

A. Pembrolizumab

B. Pembrolizumab plus single agent platinum

C. Pembrolizumab plus platinum based doublet chemotherapy

D. Platinum based doublet chemotherapy

Answer: Pembrolizumab

If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach

Previous

Which of the following is not true regarding the immune checkpoint inhibitor durvalumab?

If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach

Next

Cytotoxic chemotherapy will not be recommended in which of the following performance status of a patient with NSCLC

Related Articles

What is the most common type of bladder cancer?

What is the most common type of bladder cancer?

All of the below are symptoms of advanced bladder cancer except which one?

All of the below are symptoms of advanced bladder cancer except which one?

True or false? Bladder cancer affects mostly young women

True or false? Bladder cancer affects mostly young women

Which region in the u.s. Has the highest incidence rate of bladder cancer?

Which region in the u.s. Has the highest incidence rate of bladder cancer?

We will be happy to hear your thoughts

Leave a reply Cancel reply

You must be logged in to post a comment.